Lisata Therapeutics Stock Performance
| LSTA Stock | USD 2.58 0.15 5.49% |
The company secures a Beta (Market Risk) of -0.42, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Lisata Therapeutics are expected to decrease at a much lower rate. During the bear market, Lisata Therapeutics is likely to outperform the market. At this point, Lisata Therapeutics has a negative expected return of -0.17%. Please make sure to verify Lisata Therapeutics' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Lisata Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lisata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.92 | Five Day Return (3.37) | Year To Date Return (6.15) | Ten Year Return (99.49) | All Time Return (100.00) |
Last Split Factor 1:15 | Last Split Date 2022-09-15 |
1 | Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons Research Through Development of Next Generation Biomarker As... | 11/19/2024 |
2 | Neurogene and Ventyx Biosciences rises after insider buying by executives | 11/26/2024 |
3 | Vevo Therapeutics faz parceria com a Parse Biosciences GigaLab para gerar um atlas de 100 milhes de clulas para descoberta de medicamentos com tecnologia de IA | 12/05/2024 |
4 | Castle Biosciences CEO Derek Maetzold sells 160,741 in shares | 12/09/2024 |
5 | Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | 12/10/2024 |
6 | Why Pacific Biosciences of California Is the Worst ARK Stock to Buy According to Short Sellers | 12/11/2024 |
7 | Riassunto Parse Biosciences lancia Evercode Mouse BCR per supportare la progettazione e lo sviluppo di anticorpi per applicazioni di scoperta di farmaci | 12/12/2024 |
8 | Solid Biosciences SWOT analysis gene therapy stocks potential in DMD treatment | 12/13/2024 |
| Begin Period Cash Flow | 32.2 M | |
| Free Cash Flow | -20 M |
Lisata |
Lisata Therapeutics Relative Risk vs. Return Landscape
If you would invest 295.00 in Lisata Therapeutics on September 18, 2024 and sell it today you would lose (37.00) from holding Lisata Therapeutics or give up 12.54% of portfolio value over 90 days. Lisata Therapeutics is currently does not generate positive expected returns and assumes 3.072% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Lisata, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lisata Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lisata Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lisata Therapeutics, and traders can use it to determine the average amount a Lisata Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0542
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LSTA |
Estimated Market Risk
| 3.07 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lisata Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lisata Therapeutics by adding Lisata Therapeutics to a well-diversified portfolio.
Lisata Therapeutics Fundamentals Growth
Lisata Stock prices reflect investors' perceptions of the future prospects and financial health of Lisata Therapeutics, and Lisata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lisata Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (14.02 M) | ||||
| Shares Outstanding | 8.39 M | ||||
| Price To Book | 0.64 X | ||||
| EBITDA | (25.52 M) | ||||
| Net Income | (20.84 M) | ||||
| Cash And Equivalents | 72.99 M | ||||
| Cash Per Share | 18.07 X | ||||
| Total Debt | 305 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.33 X | ||||
| Book Value Per Share | 5.91 X | ||||
| Cash Flow From Operations | (20.03 M) | ||||
| Earnings Per Share | (2.51) X | ||||
| Market Capitalization | 21.66 M | ||||
| Total Asset | 54.69 M | ||||
| Retained Earnings | (528.08 M) | ||||
| Working Capital | 47.33 M | ||||
About Lisata Therapeutics Performance
By analyzing Lisata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Lisata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lisata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lisata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.4 K | 4.6 K | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.43) | (0.45) |
Things to note about Lisata Therapeutics performance evaluation
Checking the ongoing alerts about Lisata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lisata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lisata Therapeutics generated a negative expected return over the last 90 days | |
| Lisata Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (20.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Solid Biosciences SWOT analysis gene therapy stocks potential in DMD treatment |
- Analyzing Lisata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lisata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Lisata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lisata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lisata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lisata Therapeutics' stock. These opinions can provide insight into Lisata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |